These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 36270286)

  • 1. Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75.
    Cao Y; Song W; Wang L; Liu P; Yue C; Jian F; Yu Y; Yisimayi A; Wang P; Wang Y; Zhu Q; Deng J; Fu W; Yu L; Zhang N; Wang J; Xiao T; An R; Wang J; Liu L; Yang S; Niu X; Gu Q; Shao F; Hao X; Meng B; Gupta RK; Jin R; Wang Y; Xie XS; Wang X
    Cell Host Microbe; 2022 Nov; 30(11):1527-1539.e5. PubMed ID: 36270286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern.
    Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Stella AO; Kindinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Jean T; Foster CSP; Christ D; Hoppe AC; Munier ML; Darley D; Churchill M; Stark DJ; Matthews G; Rawlinson WD; Kelleher AD; Turville SG
    EBioMedicine; 2022 Oct; 84():104270. PubMed ID: 36130476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.
    Neerukonda SN; Wang R; Vassell R; Baha H; Lusvarghi S; Liu S; Wang T; Weiss CD; Wang W
    J Virol; 2022 Sep; 96(17):e0114022. PubMed ID: 36000843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.
    da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
    Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS
    Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution.
    Cao Y; Jian F; Wang J; Yu Y; Song W; Yisimayi A; Wang J; An R; Chen X; Zhang N; Wang Y; Wang P; Zhao L; Sun H; Yu L; Yang S; Niu X; Xiao T; Gu Q; Shao F; Hao X; Xu Y; Jin R; Shen Z; Wang Y; Xie XS
    Nature; 2023 Feb; 614(7948):521-529. PubMed ID: 36535326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75.
    Wang Q; Iketani S; Li Z; Guo Y; Yeh AY; Liu M; Yu J; Sheng Z; Huang Y; Liu L; Ho DD
    Cell Host Microbe; 2022 Nov; 30(11):1512-1517.e4. PubMed ID: 36108630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
    Xia S; Jiao F; Wang L; Yu X; Lu T; Fu Y; Huang Z; Li X; Huang J; Wang Q; Man Q; Xiong L; Jiang S; Lu L
    J Med Virol; 2023 Mar; 95(3):e28641. PubMed ID: 36890632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
    Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
    mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural and biochemical mechanism for increased infectivity and immune evasion of Omicron BA.2 variant compared to BA.1 and their possible mouse origins.
    Xu Y; Wu C; Cao X; Gu C; Liu H; Jiang M; Wang X; Yuan Q; Wu K; Liu J; Wang D; He X; Wang X; Deng SJ; Xu HE; Yin W
    Cell Res; 2022 Jul; 32(7):609-620. PubMed ID: 35641567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1.
    Wang Q; Guo Y; Schwanz LT; Mellis IA; Sun Y; Qu Y; Urtecho G; Valdez R; Stoneman E; Gordon A; Wang HH; Ho DD; Liu L
    Emerg Microbes Infect; 2024 Dec; 13(1):2359004. PubMed ID: 38779718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralization of SARS-CoV-2 Omicron subvariant BA.2.87.1.
    Lasrado N; Rössler A; Rowe M; Collier AY; Barouch DH
    Vaccine; 2024 Apr; 42(9):2117-2121. PubMed ID: 38458874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis for the evolution and antibody evasion of SARS-CoV-2 BA.2.86 and JN.1 subvariants.
    Yang H; Guo H; Wang A; Cao L; Fan Q; Jiang J; Wang M; Lin L; Ge X; Wang H; Zhang R; Liao M; Yan R; Ju B; Zhang Z
    Nat Commun; 2024 Sep; 15(1):7715. PubMed ID: 39231977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of Immune Evasion and Host Range Expansion by the SARS-CoV-2 B.1.1.529 (Omicron) Variant.
    Ren W; Zhang Y; Rao J; Wang Z; Lan J; Liu K; Zhang X; Hu X; Yang C; Zhong G; Zhang R; Wang X; Shan C; Ding Q
    mBio; 2023 Apr; 14(2):e0041623. PubMed ID: 37010428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of Spike infectivity, processing, and neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2.
    Pastorio C; Zech F; Noettger S; Jung C; Jacob T; Sanderson T; Sparrer KMJ; Kirchhoff F
    Cell Host Microbe; 2022 Sep; 30(9):1255-1268.e5. PubMed ID: 35931073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 omicron BA.1.1 is highly resistant to antibody neutralization of convalescent serum from the origin strain.
    Li J; Li X; Mao H; Huang C; Sun Y; Miao L; Li J; Song W; Zhang Y; Huang J; Chen K
    Virus Res; 2023 Jul; 332():199131. PubMed ID: 37178794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural Basis for the Enhanced Infectivity and Immune Evasion of Omicron Subvariants.
    Li Y; Shen Y; Zhang Y; Yan R
    Viruses; 2023 Jun; 15(6):. PubMed ID: 37376697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AlphaFold2-Enabled Atomistic Modeling of Structure, Conformational Ensembles, and Binding Energetics of the SARS-CoV-2 Omicron BA.2.86 Spike Protein with ACE2 Host Receptor and Antibodies: Compensatory Functional Effects of Binding Hotspots in Modulating Mechanisms of Receptor Binding and Immune Escape.
    Raisinghani N; Alshahrani M; Gupta G; Xiao S; Tao P; Verkhivker G
    J Chem Inf Model; 2024 Mar; 64(5):1657-1681. PubMed ID: 38373700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5.
    Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Hoehl S; Ciesek S; Türeci Ö; Sahin U
    Sci Immunol; 2022 Nov; 7(77):eade2283. PubMed ID: 36125366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 variants of concern: spike protein mutational analysis and epitope for broad neutralization.
    Mannar D; Saville JW; Sun Z; Zhu X; Marti MM; Srivastava SS; Berezuk AM; Zhou S; Tuttle KS; Sobolewski MD; Kim A; Treat BR; Da Silva Castanha PM; Jacobs JL; Barratt-Boyes SM; Mellors JW; Dimitrov DS; Li W; Subramaniam S
    Nat Commun; 2022 Aug; 13(1):4696. PubMed ID: 35982054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.